Showing 261 - 280 results of 363 for search '(( 10 ((meter decrease) OR (((nn decrease) OR (mean decrease)))) ) OR ( 12 c decrease ))*', query time: 0.14s Refine Results
  1. 261

    Enhancing the corrosion resistance of reinforcing steel under aggressive operational conditions using behentrimonium chloride by Radwan A.B.

    Published 2019
    “…1 of BTC, we are able to measure an inhibition efficiency of 91, 79, and 71% in SCP solution with 3.5% NaCl at pH of 12.5, 10 and 7, respectively without showing any effect on the mechanical properties on the cured mortars. …”
    Get full text
    Get full text
  2. 262
  3. 263
  4. 264
  5. 265
  6. 266
  7. 267
  8. 268
  9. 269
  10. 270
  11. 271
  12. 272
  13. 273
  14. 274
  15. 275
  16. 276

    Antiferromagnetism in EuPdGe3 by Albedah, M.A.

    Published 2014
    “…EuPdGe3 crystallizes in the BaNiSn3-type tetragonal structure (space group I4mm) with the lattice constants a=4.4457(1)Å and c=10.1703(2)Å. The results are consistent with EuPdGe3 being an antiferromagnet with the Néel temperature TN=12.16(1)K and with the Eu spins S=7/2 in the ab plane. …”
    Get full text
    Get full text
  17. 277
  18. 278

    Hypospadias Reconstruction Training: Development of an Ex-Vivo Model for Objective Evaluation of Surgical Skills by Abbas, Tariq

    Published 2025
    “…However, EMG measurements showed significant reductions in average EMG power, total time, dominant frequency, and cumulative muscle workload after training. Additionally, the mean power spectral density of the EMG signal decreased notably post-training. …”
    Get full text
    Get full text
    Get full text
    article
  19. 279

    Trends and Appropriateness of Sodium-glucose Co-transporter 2 Inhibitors Use in Qatar by Zaghloul, Nancy

    Published 2023
    “…Male gender (odds ratio [OR], 1.692; 95% confidence interval [CI], 1.015 to 2.822; P=0.044), patients with a baseline glycated hemoglobin (HbA1c) >7% (OR, 3.219; 95% CI, 1.838 to 5.637; P<0.001) and atherosclerotic cardiovascular disease (ASCVD) (OR, 2.182; 95% CI, 1.053 to 4.523), patients on metformin (OR, 7.556; 95% CI, 4.460 to 12.802; P<0.001), sulfonylureas (OR, 2.301; 95% CI, 1.160 to 4.563; P=0.017), and dipeptidyl peptidase 4 inhibitors (DPP4is) (OR, 3.430; 95% CI, 2.004 to 5.871; P<0.001) were more likely to be prescribed a SGLT2i. …”
    Get full text
  20. 280